类风湿关节炎超说明书用药分析

Analysis of Off-Label Drug Use in Rheumatoid Arthritis

目的:分析治疗类风湿关节炎症超说明书用药的合理性。方法:收集2021年7月~2022年6月我院治疗类风湿关节炎门诊处方8002份进行处方分析,通过文献资料法、数据分析法、循证评价法对超说明书用法进行合理性评价。结果:超说明书的药品包括甲氨蝶呤片、叶酸片、环磷酰胺片、泼尼松片、艾瑞昔布片,超说明书处方数占处方总数的比例为:64.121%,其中甲氨蝶呤片44.614%、叶酸片15.371%、环磷酰胺片(CTX) 0.212%、泼尼松片3.799%、艾瑞昔布片0.125%。以上药品均有国内外指南推荐使用,有较好的循证医学证据等级。结论:类风湿关节炎用药有指南推荐或合理的医学实践证据证明,患者用药有适应症,处方合理,对临床用药有一定的指导意见。

Objective: To analyze the rationality of off-label drug use for rheumatoid joint inflammation. Methods: 8002 outpatient prescriptions for the treatment of rheumatoid arthritis in our hospital from July 2021 to June 2022 were collected for prescription analysis, and the rationality of off-label use was evaluated by literature analysis, data analysis and evidence-based evaluation. Results: The off-label drugs included methotrexate tablets, folic acid tablets, cyclophosphamide tablets, prednisone tablets and imrecoxib tablets. The proportion of off-label prescriptions in the total number of prescriptions was as follows: 64.121%, including Methotrexate tablets 44.614%, folic acid tablets 15.371%, cyclophosphamide tablets (CTX) 0.212%, prednisone tablets 3.799%, and imrecoxib tablets 0.125%. The above drugs are recommended by domestic and foreign guidelines, and there is a good level of evidence-based medicine evidence. Conclusion: There are guidelines for the use of rheumatoid arthritis or reasonable medical practice evidence to prove that the patient has indica-tions for the use of drugs, the prescription is reasonable, and there are certain guiding opinions for clinical use.